SLDBSolid Biosciences Inc.

Healthcare
$6.82+23% 1Y

The financials

Solid Biosciences Inc. by the numbers

Solid Biosciences Inc. income statement, Q2 2026 against the same quarter a year earlier
Income statementQ2 2026Q2 2025Change
Operating income−$57M−$42Mn/a
Net income−$55M−$39Mn/a
Diluted EPS−$0.38−$0.42n/a

Biotechnology

Ranks #161 of 196 by RyuScore

Compare peers
AURA+0.62%
Aura Biosciences, Inc.
OABI+1.9%
OmniAb, Inc.
GUTS-7.4%
FRACTYL HEALTH, INC.
FDMT+0.79%
4D Molecular Therapeutics, Inc.
IMMX-1.9%
Immix Biopharma, Inc.
OLMA-1.5%
Olema Pharmaceuticals, Inc.